alitretinoin

03/01/2011 - "Blinded, controlled studies have found that oral alitretinoin is well tolerated and effective in the treatment of severe chronic hand eczema (CHE). "
08/01/2014 - "Clinical evaluation and assessment of the therapeutic efficacy of alitretinoin in a group of patients with chronic hand eczema refractory to topical steroid therapy."
10/01/2009 - "Alitretinoin has been shown to be effective in a randomized controlled trial, and is currently the only treatment specifically licensed for the treatment of hand eczema. "
01/01/2010 - "Oral alitretinoin (9-cis-retinoic acid) is a unique panagonist retinoid with immunomodulatory and anti-inflammatory activity that has emerged as a novel treatment for chronic hand eczema. "
09/01/2008 - "[Alitretinoin: a new treatment option for chronic refractory hand eczema]."

10/01/2001 - "A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study."
06/01/1998 - "Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer."
03/19/1997 - "Since both differentiation and apoptosis are involved in tumor regression, 9-cis-retinoic acid may be a more appropriate retinoid for clinical trials in neuroblastoma. "
03/01/2007 - "The ligand to RXRalpha, 9-cis-retinoic acid, induced the receptor breakdown in smooth muscle cells deriving from both normal and tumor tissue, whereas a MAPK-specific inhibitor was able to reduce RXRalpha levels only in leiomyoma cells. "
01/01/1994 - "Comparing all-trans- with 9-cis-retinoic acid, the latter was more effective in inhibiting tumor cell growth and in inducing synergism with interferon-gamma. "

01/01/2003 - "Two other trials involving 402 people demonstrated that topical alitretinoin was effective treatment compared to placebo among patients with cutaneous Kaposi's sarcoma. "
01/01/2007 - "We report a case of Kaposi's sarcoma treated with topical alitretinoin that had a favourable evolution in spite of an intense local reaction."
01/01/2007 - "[Kaposi's sarcoma treated with topical alitretinoin]."
10/01/2006 - "Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma: first European experience."
07/01/2005 - "Alitretinoin (9-cis-retinoic acid) is an FDA-approved topical therapy for the treatment of Kaposi sarcoma. "

07/01/2012 - "Moderate to severe chronic hand dermatitis (CHD) is not well controlled by current medical strategies; however, recent studies have shown significant improvement in patients treated with up to 6 months of oral alitretinoin (9-cis-retinoic acid). "
07/01/2012 - "Effective treatment of chronic hand dermatitis with 36 continuous months of alitretinoin administration: report of three cases."
03/01/2008 - "Orally administered alitretinoin is a safe and effective treatment for chronic hand dermatitis. "
10/01/2014 - "The treatment of moderate to severe chronic hand dermatitis (CHD) has been advanced with the introduction of alitretinoin (9-cis-retinoic acid). "
10/01/2014 - "Real-world experience with alitretinoin in a community dermatology practice setting in patients with chronic hand dermatitis."

05/15/1995 - "Synergistic inhibition of cell proliferation under treatment with 9-cis-retinoic acid and IFN-gamma was detected in the three breast cancer cell lines MCF-7, SKBR-3, and even in the RA-resistant BT-20 cells. "
11/01/2012 - "9-Cis-retinoic acid induces growth inhibition in retinoid-sensitive breast cancer and sea urchin embryonic cells via retinoid X receptor α and replication factor C3."
05/15/2001 - "The combination of tamoxifen and alitretinoin is well tolerated and has antitumor activity in metastatic breast cancer. "
05/15/2001 - "To determine the overall and dose-limiting toxicities (DLTs) of alitretinoin (9-cis-retinoic acid) in combination with tamoxifen and the pharmacokinetics of alitretinoin alone and when combined with tamoxifen in patients with metastatic breast cancer. "
05/15/2001 - "Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations."